Will larotrectinib be included in medical insurance coverage in 2025?

Larotrectinib is a targeted therapy drug mainly used to treat tumors with NTRK gene rearrangements, including non-small cell lung cancer, colorectal cancer, soft tissue sarcoma and other tumor types. In 2025, larotrectinib has been launched in the Chinese market and has been included in the scope of medical insurance. This means that patients can purchase it domestically and enjoy the support of the medical insurance reimbursement policy. Especially for those patients who meet the diagnosis of NTRK gene rearrangement, larotrectinib provides an effective treatment option.

Although larotrectinib has been included in medical insurance, the price of its original drug is relatively high, with a box of the original drug costing about 20,000 yuan. Due to the high price, patients may have to face certain financial pressure when choosing medications. Specific medical insurance reimbursement policies vary by region. Patients can consult with local hospital pharmacies to learn about specific reimbursement ratios and conditions. This leaves some patients with potentially affordable treatment options.

It is worth mentioning that generic versions of larotrectinib are also available in overseas markets, which provides a more economical treatment option for some patients. The price of the Laotian generic version of larotrectinib is relatively affordable, with a box selling for between a few hundred yuan and more than a thousand yuan. Compared with original drugs, generic drugs are much cheaper, but their drug ingredients and therapeutic effects are basically the same as original drugs, so they have become the first choice for many patients.

In general, although the original drug of larotrectinib is relatively expensive, it has been launched in China and is included in medical insurance, making it easier for patients to obtain treatment. For patients with higher financial burdens, generic drugs provide more affordable treatment options. Regardless of whether they choose the original drug or a generic drug, the therapeutic effect and similarity of the drug ingredients of larotrectinib provide patients with strong support and help them effectively treat tumors related to NTRK gene rearrangements.

Reference materials:https://www.vitrakvi.com/